arrow
R

Rokeya Tasneen

Johns Hopkins University
H指数:25
被引数:2,486

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models

靶向药物耐受性结核分枝杆菌持续状态免疫疗法可加速临床前模型中的结核病治愈

2026-04-010
PRE
Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis
2024-11-061
OAAI
An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis
2022-09-163
OAAI
GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment
2022-06-2128
OA
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models

贝达喹啉-吡嗪酰胺联合莫西沙星、利福布汀、德拉曼和/或OPC-167832治疗小鼠结核模型的新方案

2022-04-1923
OA
Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments
2022-04-1912
OAAI
Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis

在结核病的鼠模型中,Pretomanid对含有利奈唑胺或莫西沙星和吡嗪酰胺的贝达喹啉的新方案的贡献

2019-05-0174
OAAI
Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis
2018-07-0133
OAAI